



Risk factors, Diagnosis and Management of invasive candidiasis and candidemia in adult intensive care unit patients

**Essay Submitted for Partial Fulfillment of Master Degree In
Intensive Care Medicine**

By

Hesham Ahmed Elnady Elsayed khafaga

M.B.B.CH (2006)

Faculty of Medicine

Tanta University

Under supervision of

Prof. Dr. Galal Adel Elkady

Professor of Anesthesiology and Intensive Care

Faculty of Medicine

Ain Shams University

Dr. Alfred Morris Saeed

Assistant professor of Anesthesiology and Intensive Care

Faculty of Medicine

Ain Shams University

Dr. Mohamed Mohamed Abdel Fattah

Lecturer of Anesthesiology and Intensive Care

Faculty of Medicine

Ain Shams University

Faculty of Medicine

Ain Shams University

2015



Acknowledgment

*Thanks first and last to **ALLAH** as we owe Him for His great care, support and guidance in every step in our life.*

*I would like to express my deep gratefulness to Professor **Dr. Prof. Dr. Galal Adel Elkady**, Professor of anesthesia and intensive care Faculty of Medicine - Ain Shams University, for his concern, his guidance and continuous encouragement. I consider myself very fortunate to work under his supervision.*

*I am grateful to **Dr. Alfred Morris Saeed** Assistant Professor of anesthesia and intensive care Faculty of Medicine - Ain Shams University, for his generous and continuous help and valuable suggestions as well as his desire to achieve perfection. His great help was very impressive and his meticulous reading and enormous assistance should be appreciated.*

*I am also grateful to **Dr. Mohamed Mohamed Abdel Fattah** Lecturer of anesthesia and intensive care Faculty of Medicine - Ain Shams University for his generous and continuous help and valuable suggestions as well as his desire to achieve perfection. His great help was very impressive and his meticulous reading and enormous assistance should be appreciated.*

*I must also express my thanks to all my **family** and my **colleagues** who helped me in this essay .*

LIST OF CONTENTS

| Title | page |
|--|------|
| Acknowledgement | |
| List of Contents | |
| List of Tables | |
| List of Figures | |
| List of abbreviations | |
| Introduction | 1 |
| Chapter 1: Patient groups and risk factors of invasive candidiasis and candidemia in intensive care unit. | 3 |
| Chapter 2: Diagnosis of invasive candidiasis and candidemia | 13 |
| Chapter3: Treatment of invasive candidiasis and candidemia | 45 |
| Summary | 79 |
| References. | 83 |
| Arabic summary | |

LIST OF ABBREVIATION

| Abb | |
|--------|---|
| AmB | Amphoterecin B |
| APACHE | Acute Physiology and Chronic Health Evaluation |
| BAL | Bronchoalveolar lavage |
| BC | Blood culture |
| Bid | Twice daily |
| BSIs | Blood stream infections |
| CAGTA | C. albicans germ-tube antibodies |
| CBC | Complete blood cell count |
| Crcl | Creatinine clearance |
| CS | Candida score |
| CT | Computerized tomography |
| CVC | Central venous catheter |
| ESCMID | European Society of Clinical Microbiology and Infectious Diseases |
| FC | Fluorocytosine |
| FDA | Food and Drug Administration |
| FISH | Fluorescent in situ hybridization |
| FLC | Fluconazole |
| GM | Galactomannan |
| GI | Gastrointestinal |
| IC | Invasive candidiasis |
| ICU | Intensive care unit |
| IDSA | Infectious disease society of america |
| IFD | Invasive fungal disease |
| ITC | Itraconazole. |
| IFI | Invasive fungal infection |
| IQR | Interquartile range |

| | |
|-----------|--|
| IV | Intra venous |
| KTC | Ketoconazole |
| LOS | Length of stay |
| lip Am B | liposomal amphotericin B |
| Ld | Loading dose |
| MALDITOF- | Matrix-assisted laser desorption ionization time of flight mass- |
| MS | spectrometry |
| MICs | Minimum inhibitory concentrations |
| Ms | Modest activity |
| MV | Mechanical ventilation |
| NPV | Negative predictive value |
| NA | Not assessed |
| NAS | Non- albicans species |
| PCR | Polymerase chain reaction |
| PCT | Procalcitonin |
| PO | Per oral |
| PPV | Positive predictive value |
| Qid | Four times daily |
| R | Resistant |
| RC | Resistance depending on the concentration |
| S | Susceptible |
| SDd | Susceptible dependent on dose |
| SEN | Sensitivity |
| SICU | Surgical intensive care unit |
| SOAP | Sepsis Occurrence in Acutely Ill Patients |
| SPE | Spesifity |

LIST OF FIGURES

| Figure no. | Title | Page |
|------------|--|------|
| 1 | Various morphological forms of candida albicans. | 13 |
| 2 | Transverse section CT scan at the level of the lower pulmonary veins shows multiple ill defined bilateral nodules with a surrounding halo of ground glass opacity. | 18 |
| 3 | Practical approach of patient at risk of invasive candidiasis. | 31 |
| 4 | Concept of antifungal treatments in critically ill patients (<i>Senn et al., 2009</i>). | 32 |
| 5 | Blood film stained with may-grunwald-giemsa | 34 |
| 6 | Suggested treatment algorithm for the ICU patient with invasive candidiasis | 70 |
| 7 | Types of treatment for suspected candidiasis in the critically ill | 78 |

LIST OF TABLES

| Table no. | Table content | Page |
|------------------|--|-------------|
| 1 | Candidemia risk factors for hospitalized patients. | 4 |
| 2 | Microbiological tools to diagnosis invasive candidiasis in ICU settings. | 38 |
| 3 | Meta-analysis of antifungal prophylaxis in non-neutropenic critically ill and surgical patients: comparison of five recent systematic reviews | 50 |
| 4 | Consideration of risk of invasive fungal infections (IFI) in assessing the impact of fluconazole prophylaxis among critically ill and surgical patients | 52 |
| 5 | Currently available and late development antifungals for the treatment of invasive candidiasis | 62 |
| 6 | Spectrum of antifungal drugs, usual dose in invasive infections and dose adjustment in renal failure | 65 |
| 7 | Suggested treatment of documented candidaemia/invasive candidiasis in non neutropenic patients according to different guidelines | 69 |
| 8 | Recommended therapy for localized forms of invasive candidiasis according to 2009 IDSA guidelines | 71 |

Introduction

Candida is part of our normal microbial flora on mucosal surfaces, from where it may cause local infections like thrush in the oral cavity and candida vaginitis. However, in patients with various underlying diseases or host factors, candida may cause invasive candidiasis, most often as bloodstream infection (candidaemia) with or without secondary dissemination to the eyes, liver, spleen, bones, heart valves, central nervous system or as deep-seated candidiasis, such as peritonitis after gastrointestinal surgery. The overall mortality (within 30 day) associated with candidaemia is around 30–40% and depends on the severity of underlying disease, the candida species involved, and timing and choice of antifungal treatment (*Hassan et al.,2009*).

In population-based studies, the most important patient groups associated with invasive candidiasis are the following:

- 1- Neonates especially if being low-birth weight or preterm babies.
- 2-Critically ill patients especially if having severe disease and a long term stay in ICU.
- 3- Patients undergoing abdominal surgery especially if complicated or repeated.
- 4-Patients with malignant disease or acute necrotizing pancreatitis.
- 5-Transplant recipients.
- 6-Burn patients especially if burns involve larger body surface area or full thickness area. (*Vardakas et al., 2009*).

The severity of the underlying disease is an important factor for mortality after systemic infection, overall mortality is consistently higher in candidaemic ICU patients than other candidemic patient in general.

Invasive candidiasis manifests as either isolated candidaemia, invasive candidiasis without documented candidaemia or a combination of the two (*Leroy et al., 2009*).

The treatment of invasive candidiasis and candidemia can be schematically described as prophylactic, pre-emptive, empiric or curative. Prophylactic treatment covers all the situations where the patient is not infected and lacks the signs and symptoms of infection. In pre-emptive treatment, based on evaluation of the patient's risk factors combined with positive surrogate markers of infection, the goal is to decrease candida-related mortality. Empiric therapy describes individuals with symptoms of infection with no obvious source who merit therapy based on clinical grounds. Finally, curative treatment focuses on a microbiologically documented pathogen (*Parkins et al., 2007*).

Patient groups and risk factors

Invasive fungal infections are increased in patients admitted to intensive care units and are associated with high mortality rates. The majority of these life-threatening infections are caused by opportunistic pathogens that belong to the genus *Candida*, and *C. albicans* represents the most common cause (*Conciaet al., 2009*).

In the past, invasive fungal disease (IFD) was more commonly found in patients who were neutropenic, had received a solid organ transplant or had been treated with corticosteroids or cytotoxic agents (*Kauffman., 2006*).

The incidence rate for invasive fungal infections has increased globally over the past 2 to 3 decades, especially in healthcare settings. Along with this trend, these infections occurred more often in the non neutropenic critically ill patients than in those patients who were neutropenic or had received organ transplantation in the past. *Candida* species comprised the majority of these pathogenic fungi (*Arendrup et al., 2009*).

Before considering treatment issues, clinicians must appreciate the risk factors for fungal BSIs. Through understanding the issues and variables that heighten the potential for candidemia, one can focus on efforts not only at prevention but also on prompt diagnosis and treatment. Common risk factors predisposing to candidemia include candidal colonization, prior exposure to antibiotics, renal failure, presence of a central venous catheter (CVC), and need for total parenteral nutrition (TPN) (*Blumberg et al., 2001*).

Certain hospitalized individuals are well known to be at risk for acquiring candidemia during hospitalization as a result of their underlying medical condition, including patients with hematologic malignancies or neutropenia, patients undergoing gastrointestinal surgery, premature infants, and elderly persons (*Eggimann et al., 2003*).

Within these high-risk groups, additional risk factors have been recognized, and these specific exposures have not changed significantly during the past 2–3 decades. The presence of vascular catheters, exposure to broad-spectrum antimicrobial agents, renal failure, mucosal colonization with candida species, prolonged ICU stay, and total parenteral nutrition are all recognized to increase the risk for nosocomial candidemia (*Puzniak et al., 2004*).

TABLE1: Candidemia risk factors for hospitalized patients(*Ostrosky-Zeichner and Pappas, 2006*).

| Risk factors | Possible role in infection |
|--------------------------|--|
| Antimicrobial agents | Promote fungal colonization |
| Adrenal corticosteroid | Immuno-suppression |
| Age | Immuno-suppression |
| Chemotherapy | Immuno-suppression Mucosal disruption |
| Malignancy | Immuno-suppression |
| Previous colonization | Translocation across mucosa |
| Gastric acid suppression | Colonization and translocation |

| | |
|---|--|
| Indwelling catheter | Direct vascular access |
| Central venous catheter | Contaminated product Pressure transducer |
| TPN | Direct vascular access Hyperglycemia Contamination of infusate |
| Neutropenia ($<500/\text{mm}^3$) | Immuno-suppression |
| Surgery (gastrointestinal) | Route of infection Direct vascular access |
| Mechanical ventilation | Route of infection |
| Renal failure/hemodialysis | Route of infection Immuno-suppression |
| Malnutrition | Immuno-suppression |
| Hospital or intensive care unit stay | Exposure to pathogens Exposure to additional risk factors |
| Severity of disease. | Immuno-suppression Invasive procedures |

Analysis of risk factors:

The risk factors examined varied between the studies. All the risk factors that were identified as statistically significant associated with IFD in one or more of the 10 studies that carried out a multivariable analysis. Candidate risk factors, in descending order are described below.

1. Surgery:

Seven studies examined the association between surgery and IFD. The type and timing of surgery varied across the studies, with two looking at abdominal surgery and the others looking at any surgical procedure. Five of the seven studies reported a significant association between surgery and invasive fungal diseases(IFD) on both univariable and multivariable analyses(*Chow et al., 2008*).

Injury, trauma, and blood loss in surgical patients, which result in marked depression in cell-mediated immunity, may specifically be associated with high incidence of invasive fungal infection (IFI). However, some factors other than underlying disease and characteristics of patients admitted to the ICU may also contribute to the high incidence. First, some of the patients were diagnosed as having IFI but without biopsy, which may lead to enrollment of patients with fungal colonization and overestimation of IFI in surgical patients with severe sepsis. Second, most of the enrolled patients with severe sepsis had been hospitalized in the surgical wards before their ICU admission and hence, they were more susceptible to nosocomial fungal infection (*Volk., 2002*).

2. Total parenteral nutrition:

Six of the twelve studies assessed total parenteral nutrition as a risk factor, and all found a significant association with IFD on univariable analysis (*Chow et al., 2008*).

3. Fungal colonization:

Candida colonization should be addressed as a risk factor and not as an infection itself. This is particularly true when the colonization index (an index based on the number of positive sites/cultured sites) increases (*Piazza et al., 2004*).

Fungal colonisation has been associated with the development of invasive candidiasis IC. Yet, a small proportion(3%–25%) of colonized patients subsequently develop invasive disease(*Agvald-Ohman et al., 2008*).

Different risk factors for invasive candidiasis, including prior *Candida* species colonization, could allow recognition of patients at highest risk. Such patients may be potential candidates for preemptive antifungal therapy(*Piarroux et al., 2004*).

Colonization was defined as the presence of *Candida* species in non significant samples obtained from the oropharynx, stomach, urine, or tracheal aspirates. Colonization was considered unifocal when *Candida* species were isolated from one focus and multifocal when *Candida* species were simultaneously isolated from various non contiguous foci, even if two different *Candida* species were isolated, oropharynx and stomach were considered one site (digestive focus).

Unifocal and multifocal colonization persistence was defined by at least two weekly consecutive sets of candida positive cultures (*León et al., 2006*).

Patients were classified into three groups as follows:

- a. Neither colonized nor infected,
- b. Unifocal or multifocal candida species colonization without proven infection,
- c. Proven candidal infection (*León et al., 2006*).

Candida colonization could be found in the respiratory samples obtained by broncho-alveolar lavage (BAL), endotracheal aspirate or protected specimen brushing in critically ill patients. Since patients with chronic lung pathology provide a suitable nidus for fungal colonization, screening such patients for fungal colonization of the respiratory tract would enable us to identify individuals requiring closer monitoring for the development of possible complications like acute invasive fungal infection or dissemination via hematogenous spread (*Delisle et al., 2011*).

4-Renal replacement therapy:

Seven studies examined renal replacement therapy as a risk factor for IFD, of which five found a significant association on univariable analysis(*Jordà-Marcos et al., 2007*).